{"url":"https://lda.senate.gov/api/v1/filings/e32245b4-c50f-402d-b5be-e5a02ed333d8/","filing_uuid":"e32245b4-c50f-402d-b5be-e5a02ed333d8","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2024,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/e32245b4-c50f-402d-b5be-e5a02ed333d8/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"David Zook","dt_posted":"2024-07-22T15:19:13-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1500 K St NW","registrant_address_2":"Suite 1100","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":12631,"url":"https://lda.senate.gov/api/v1/registrants/12631/","house_registrant_id":31801,"name":"FAEGRE DRINKER BIDDLE & REATH LLP","description":"Law firm","address_1":"1500 K St NW","address_2":"Suite 1100","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DAVID ZOOK","contact_telephone":"+1 202-312-7414","dt_updated":"2026-07-30T11:30:36.878220-04:00"},"client":{"id":57569,"url":"https://lda.senate.gov/api/v1/clients/57569/","client_id":57569,"name":"INFLARX PHARMACEUTICALS, INC.","general_description":"Pharmaceutical company.","client_government_entity":null,"client_self_select":false,"state":"MI","state_display":"Michigan","country":"US","country_display":"United States of America","ppb_state":"MI","ppb_state_display":"Michigan","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-07-27"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"NIH panel review of GOHIBIC.","foreign_entity_issues":"InflaRx N.V., identified on Registration (LD-1), is the parent company of the registrant and would be impacted by the above issue.","lobbyists":[{"lobbyist":{"id":79437,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":"RUSGAN","last_name":"ZOOK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145682,"prefix":"mr","prefix_display":"MR.","first_name":"TIMOTHY","nickname":null,"middle_name":"R.","last_name":"FRANSON","suffix":"md","suffix_display":"MD"},"covered_position":null,"new":false}],"government_entities":[{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}